Dermata Therapeutics, Inc.(DRMA)

Biotechnology · San Diego, CA

$1.11+0.01 (+0.45%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T12:51:16.049Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:51:16.049Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,464,579
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 4,412,764
TTM free cash flow · period ending 2026-06-30: -8,144,925

FMP input reference: 7afec7845e5c1de7d6a7da79415c7f2016586588c7dc262303e5dc1b6d25f1da

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DRMA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

DRMA Competitors' EV/FCF Ratio

DRMA

Dermata Therapeutics, Inc.

Current

Market Cap

$4.46M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLGN

CollPlant Biotechnologies Ltd.

vs DRMA

Market Cap

$4.42M

EV/FCF Ratio

N/A

TTM Avg

57.42x

3Y Avg

57.42x

5Y Avg

57.42x

ERNA

Ernexa Therapeutics Inc.

vs DRMA

Market Cap

$4.41M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIDX

20/20 Biolabs Inc.

vs DRMA

Market Cap

$4.32M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GRI

GRI Bio, Inc.

vs DRMA

Market Cap

$4.18M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BGMS

Bio Green Med Solution, Inc.

vs DRMA

Market Cap

$4.79M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs DRMA

Market Cap

$4.85M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMGL

Basel Medical Group Ltd Ordinary Shares

vs DRMA

Market Cap

$4.96M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GELS

Gelteq Limited Ordinary Shares

vs DRMA

Market Cap

$4.99M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

APVO

Aptevo Therapeutics Inc.

vs DRMA

Market Cap

$3.94M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Dermata Therapeutics, Inc. (DRMA)	$4.46M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.42M	N/A	57.42x	57.42x	57.42x
Ernexa Therapeutics Inc. (ERNA)vs ›	$4.41M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.32M	N/A	N/A	N/A	N/A
GRI Bio, Inc. (GRI)vs ›	$4.18M	N/A	N/A	N/A	N/A
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.79M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.85M	N/A	N/A	N/A	N/A
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$4.96M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$4.99M	N/A	N/A	N/A	N/A
Aptevo Therapeutics Inc. (APVO)vs ›	$3.94M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

DRMA EV/FCF Ratio Metrics

DRMA Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics